Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $310.63 million. The enterprise value is $29.73 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 14.26 million shares outstanding. The number of shares has increased by 111.87% in one year.
| Current Share Class | 14.26M |
| Shares Outstanding | 14.26M |
| Shares Change (YoY) | +111.87% |
| Shares Change (QoQ) | +7.84% |
| Owned by Insiders (%) | 10.92% |
| Owned by Institutions (%) | 50.55% |
| Float | 3.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 335.81 |
| Forward PS | n/a |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.03, with a Debt / Equity ratio of 0.04.
| Current Ratio | 21.03 |
| Quick Ratio | 20.80 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8,157.82 |
Financial Efficiency
Return on equity (ROE) is -34.97% and return on invested capital (ROIC) is -22.95%.
| Return on Equity (ROE) | -34.97% |
| Return on Assets (ROA) | -21.97% |
| Return on Invested Capital (ROIC) | -22.95% |
| Return on Capital Employed (ROCE) | -29.79% |
| Revenue Per Employee | $8,645 |
| Profits Per Employee | -$755,794 |
| Employee Count | 107 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.06% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.06% |
| 50-Day Moving Average | 19.96 |
| 200-Day Moving Average | 22.36 |
| Relative Strength Index (RSI) | 54.39 |
| Average Volume (20 Days) | 133,411 |
Short Selling Information
The latest short interest is 2.55 million, so 17.90% of the outstanding shares have been sold short.
| Short Interest | 2.55M |
| Short Previous Month | 2.21M |
| Short % of Shares Out | 17.90% |
| Short % of Float | 76.16% |
| Short Ratio (days to cover) | 11.13 |
Income Statement
In the last 12 months, Neurogene had revenue of $925,000 and -$80.87 million in losses. Loss per share was -$4.35.
| Revenue | 925,000 |
| Gross Profit | -64.20M |
| Operating Income | -89.74M |
| Pretax Income | -55.44M |
| Net Income | -80.87M |
| EBITDA | -86.55M |
| EBIT | -89.74M |
| Loss Per Share | -$4.35 |
Full Income StatementBalance Sheet
The company has $292.60 million in cash and $11.71 million in debt, giving a net cash position of $280.90 million or $19.70 per share.
| Cash & Cash Equivalents | 292.60M |
| Total Debt | 11.71M |
| Net Cash | 280.90M |
| Net Cash Per Share | $19.70 |
| Equity (Book Value) | 291.80M |
| Book Value Per Share | 19.54 |
| Working Capital | 282.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$69.73 million and capital expenditures -$1.52 million, giving a free cash flow of -$71.25 million.
| Operating Cash Flow | -69.73M |
| Capital Expenditures | -1.52M |
| Free Cash Flow | -71.25M |
| FCF Per Share | -$5.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -9,701.19% |
| Pretax Margin | -8,742.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -111.87% |
| Shareholder Yield | -111.87% |
| Earnings Yield | -26.03% |
| FCF Yield | -22.94% |
Analyst Forecast
The average price target for Neurogene is $41.86, which is 92.20% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.86 |
| Price Target Difference | 92.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 114.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neurogene has an Altman Z-Score of 10.01 and a Piotroski F-Score of 2.
| Altman Z-Score | 10.01 |
| Piotroski F-Score | 2 |
